Disclosed herein are methods to reliably and robustly generate a pure population of airway basal cells that are capable of producing a normal mucociliary epithelium. Such basal cells may be used to treat chronic respiratory diseases, such as cystic fibrosis, chronic obstructive pulmonary disease, and asthma.

The present disclosure relates to methods of inducing tolerance to lung allograft transplantation. These methods comprise increasing suppressor CD8.sup.+ T cells and/or suppressing deleterious CD8+ and CD4.sup.+ T cells.

A method of producing an organoid derived from a lung epithelial cell or a lung cancer cell, comprising culturing a sample including the lung epithelial cell or the lung cancer cell in a culture medium, wherein the culture medium contains 0-10% (v/v) extracellular matrix, and a combination of at least one selected from the group consisting of keratinocyte growth factor (KGF), fibroblast growth factor (FGF) 10, and hepatocyte growth factor (HGF); bone morphogenetic protein (BMP) inhibitor; and TGFβ inhibitor, and the culture medium is substantially free of feeder cells.

The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.

System and method includes a body having a central microchannel separated by one or more porous membranes. The membranes are configured to divide the central microchannel into a two or more parallel central microchannels, wherein one or more first fluids are applied through the first central microchannel and one or more second fluids are applied through the second or more central microchannels. The surfaces of each porous membrane can be coated with cell adhesive molecules to support the attachment of cells and promote their organization into tissues on the upper and lower surface of the membrane. The pores may be large enough to only permit exchange of gases and small chemicals, or to permit migration and transchannel passage of large proteins and whole living cells. Fluid pressure, flow and channel geometry also may be varied to apply a desired mechanical force to one or both tissue layers.

A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20 to about 22 weeks of gestation. Methods of using the pharmaceutical composition are also disclosed.

Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.

Described herein are particular infection model systems, methods of studying infection, and method of screening compounds in various model systems. Particularly, SARS-CoV-2 is studied in these organ and infection models.

This invention relates generally to the discovery of novel mammalian lung spheroids and lung spheroid cells and uses thereof.

Disclosed herein are devices that include a top chamber including at least one port, a bottom chamber including at least one inlet and at least one outlet, wherein the opening of the at least one inlet is smaller than the opening of the at least one outlet, and a membrane located between the top chamber and the bottom chamber, wherein the membrane is fluidly coupled with the top chamber and the bottom chamber. Also disclosed herein are systems including the disclosed devices. The systems include liquid in one or more of the chambers of the device. Methods of using the devices and systems include producing a vacuum by flowing a liquid through the bottom chamber of the system. Due to the difference in size of the inlet and outlet in the bottom chamber, a vacuum is produced in the top chamber.